{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:43:06Z","timestamp":1791477786240,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000027","name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA017830"],"award-info":[{"award-number":["AA017830"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA018779"],"award-info":[{"award-number":["AA018779"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA027486"],"award-info":[{"award-number":["AA027486"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism"},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["AG072898"],"award-info":[{"award-number":["AG072898"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psychotic disorders are currently diagnosed by examining the patient\u2019s mental state and medical history. Identifying reliable diagnostic, monitoring, predictive, or prognostic biomarkers would be useful in clinical settings and help to understand the pathophysiology of schizophrenia. Here, we performed an untargeted metabolomics analysis using ultra-high pressure liquid chromatography coupled with time-of-flight mass spectroscopy on cerebrospinal fluid (CSF) and serum samples of 25 patients at their first-episode psychosis (FEP) manifestation (baseline) and after 18 months (follow-up). CSF and serum samples of 21 healthy control (HC) subjects were also analyzed. By comparing FEP and HC groups at baseline, we found eight CSF and 32 serum psychosis-associated metabolites with non-redundant identifications. Most remarkable was the finding of increased CSF serotonin (5-HT) levels. Most metabolites identified at baseline did not differ between groups at 18-month follow-up with significant improvement of positive symptoms and cognitive functions. Comparing FEP patients at baseline and 18-month follow-up, we identified 20 CSF metabolites and 90 serum metabolites that changed at follow-up. We further utilized Ingenuity Pathway Analysis (IPA) and identified candidate signaling pathways involved in psychosis pathogenesis and progression. In an extended cohort, we validated that CSF 5-HT levels were higher in FEP patients than in HC at baseline by reversed-phase high-pressure liquid chromatography. To conclude, these findings provide insights into the pathophysiology of psychosis and identify potential psychosis-associated biomarkers.<\/jats:p>","DOI":"10.1038\/s41398-022-02000-1","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T13:03:39Z","timestamp":1654261419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Identification of cerebrospinal fluid and serum metabolomic biomarkers in first episode psychosis patients"],"prefix":"10.1038","volume":"12","author":[{"given":"Pei","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4989-8782","authenticated-orcid":false,"given":"Ada Man-Choi","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Tufvesson-Alm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline W.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Orhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6068-5329","authenticated-orcid":false,"given":"Feride","family":"Eren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1659-5232","authenticated-orcid":false,"given":"G\u00f6ran","family":"Engberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilly","family":"Schwieler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Fatouros-Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Imbeault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Iverson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-5219","authenticated-orcid":false,"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8103-6977","authenticated-orcid":false,"given":"Simon","family":"Cervenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl M.","family":"Sellgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7359-5250","authenticated-orcid":false,"given":"Sophie","family":"Erhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6796-9938","authenticated-orcid":false,"given":"Doo-Sup","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"2000_CR1","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1176\/appi.ajp.2019.19080865","volume":"176","author":"JA Lieberman","year":"2019","unstructured":"Lieberman JA, Small SA, Girgis RR. Early detection and preventive intervention in schizophrenia: from fantasy to reality. Am J Psychiatry. 2019;176:794\u2013810.","journal-title":"Am J Psychiatry"},{"key":"2000_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fpsyt.2020.00613","volume":"11","author":"SF Sonnenschein","year":"2020","unstructured":"Sonnenschein SF, Gomes FV, Grace AA. Dysregulation of midbrain dopamine system and the pathophysiology of schizophrenia. Front Psychiatry. 2020;11:613.","journal-title":"Front Psychiatry"},{"key":"2000_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02442-4","volume":"7","author":"DJ Hinton","year":"2017","unstructured":"Hinton DJ, Vazquez MS, Geske JR, Hitschfeld MJ, Ho AMC, Karpyak VM, et al. Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects. Sci Rep. 2017;7:2496.","journal-title":"Sci Rep."},{"key":"2000_CR4","doi-asserted-by":"publisher","first-page":"a000588","DOI":"10.1101\/mcs.a000588","volume":"1","author":"CB Clish","year":"2015","unstructured":"Clish CB. Metabolomics: an emerging but powerful tool for precision medicine. Cold Spring Harb Mol Case Stud. 2015;1:a000588.","journal-title":"Cold Spring Harb Mol Case Stud."},{"key":"2000_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41537-016-0001-5","volume":"3","author":"PF Buckley","year":"2017","unstructured":"Buckley PF, Miller BJ. Personalized medicine for schizophrenia. NPJ Schizophr. 2017;3:2.","journal-title":"NPJ Schizophr."},{"key":"2000_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.schres.2017.09.021","volume":"195","author":"J Davison","year":"2018","unstructured":"Davison J, O\u2019Gorman A, Brennan L, Cotter DR. A systematic review of metabolite biomarkers of schizophrenia. Schizophr Res. 2018;195:32\u201350.","journal-title":"Schizophr Res."},{"key":"2000_CR7","doi-asserted-by":"publisher","first-page":"e756","DOI":"10.1371\/journal.pone.0000756","volume":"2","author":"JT Huang","year":"2007","unstructured":"Huang JT, Leweke FM, Tsang TM, Koethe D, Kranaster L, Gerth CW, et al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One. 2007;2:e756.","journal-title":"PLoS One"},{"key":"2000_CR8","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1021\/ac901536h","volume":"81","author":"AM Evans","year":"2009","unstructured":"Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography\/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009;81:6656\u201367.","journal-title":"Anal Chem"},{"key":"2000_CR9","doi-asserted-by":"publisher","first-page":"46.","DOI":"10.3389\/fnbeh.2016.00046","volume":"10","author":"JR Ayers-Ringler","year":"2016","unstructured":"Ayers-Ringler JR, Oliveros A, Qiu YY, Lindberg DM, Hinton DJ, Moore RM. Label- Free Proteomic Analysis of Protein Changes in the Striatum during Chronic Ethanol Use and Early Withdrawal. Front Behav Neurosci. 2016;10:46.","journal-title":"Front Behav Neurosci"},{"key":"2000_CR10","first-page":"CD001257","volume":"3","author":"CB Joy","year":"2006","unstructured":"Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev. 2006;3:CD001257.","journal-title":"Cochrane Database Syst Rev."},{"key":"2000_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/sleep\/14.2.133","volume":"14","author":"KL Benson","year":"1991","unstructured":"Benson KL, Faull KF, Zarcone VP Jr. Evidence for the role of serotonin in the regulation of slow wave sleep in schizophrenia. Sleep. 1991;14:133\u20139.","journal-title":"Sleep."},{"key":"2000_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0165-1781(95)02741-6","volume":"59","author":"HC Tuckwell","year":"1996","unstructured":"Tuckwell HC, Koziol JA. On the concentration of 5-hydroxyindoleacetic acid in schizophrenia: A meta-analysis. Psychiat Res. 1996;59:239\u201344.","journal-title":"Psychiat Res."},{"key":"2000_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0165-1781(98)00090-0","volume":"81","author":"IM Wieselgren","year":"1998","unstructured":"Wieselgren IM, Lindstrom LH. CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Psychiat Res. 1998;81:101\u201310.","journal-title":"Psychiat Res"},{"key":"2000_CR14","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","volume":"27","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuro-Psychoph. 2003;27:1159\u201372.","journal-title":"Prog Neuro-Psychoph."},{"key":"2000_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0920-9964(94)00043-8","volume":"14","author":"A Breier","year":"1995","unstructured":"Breier A. Serotonin, Schizophrenia and Antipsychotic Drug-Action. Schizophrenia Res. 1995;14:187\u2013202.","journal-title":"Schizophrenia Res."},{"key":"2000_CR16","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3390\/molecules23082087","volume":"23","author":"P Stepnicki","year":"2018","unstructured":"Stepnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules. 2018;23:2087","journal-title":"Molecules"},{"key":"2000_CR17","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.2174\/138920112800784880","volume":"13","author":"HY Meltzer","year":"2012","unstructured":"Meltzer HY, Massey BW, Horiguchi M. Serotonin Receptors as Targets for Drugs Useful to Treat Psychosis and Cognitive Impairment in Schizophrenia. Curr Pharm Biotechno. 2012;13:1572\u201386.","journal-title":"Curr Pharm Biotechno."},{"key":"2000_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","volume":"64","author":"HY Meltzer","year":"2013","unstructured":"Meltzer HY. Update on Typical and Atypical Antipsychotic Drugs. Annu Rev Med. 2013;64:393\u2013406.","journal-title":"Annu Rev Med."},{"key":"2000_CR19","first-page":"587","volume":"43","author":"HY Meltzer","year":"1991","unstructured":"Meltzer HY, Nash JF. Effects of Antipsychotic-Drugs on Serotonin Receptors .7. Pharm Rev. 1991;43:587\u2013604.","journal-title":"Pharm Rev."},{"key":"2000_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/acps.12854","volume":"137","author":"B Galling","year":"2018","unstructured":"Galling B, Vernon JA, Pagsberg AK, Wadhwa A, Grudnikoff E, Seidman AJ, et al. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand. 2018;137:187\u2013205.","journal-title":"Acta Psychiatr Scand."},{"key":"2000_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/261717a0","volume":"261","author":"P Seeman","year":"1976","unstructured":"Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic\/dopamine receptors. Nature 1976;261:717\u20139.","journal-title":"Nature"},{"key":"2000_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41398-017-0071-9","volume":"8","author":"JP Kesby","year":"2018","unstructured":"Kesby JP, Eyles DW, McGrath JJ, Scott JG. Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl Psychiat. 2018;8:30","journal-title":"Transl Psychiat"},{"key":"2000_CR23","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1038\/sj.npp.1301597","volume":"33","author":"A Soliman","year":"2008","unstructured":"Soliman A, O\u2019Driscoll GA, Pruessner J, Holahan ALV, Boileau I, Gagnon D. et al. Stressinduced dopamine release in humansat risk of psychosis: a [C-11]raclopride PET study. Neuropsychopharmacol. 2008;33:2033\u201341.","journal-title":"Neuropsychopharmacol"},{"key":"2000_CR24","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/mp.2011.20","volume":"16","author":"O Howes","year":"2011","unstructured":"Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatr 2011;16:885\u20136.","journal-title":"Mol Psychiatr"},{"key":"2000_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature16549","volume":"530","author":"A Sekar","year":"2016","unstructured":"Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature 2016;530:177\u201383.","journal-title":"Nature"},{"key":"2000_CR26","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/mp.2009.52","volume":"14","author":"J Soderlund","year":"2009","unstructured":"Soderlund J, Schroder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H, et al. Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry. 2009;14:1069\u201371.","journal-title":"Mol Psychiatry."},{"key":"2000_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1503\/jpn.140126","volume":"40","author":"L Schwieler","year":"2015","unstructured":"Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia-significance for activation of the kynurenine pathway. J Psychiatry Neurosci. 2015;40:126\u201333.","journal-title":"J Psychiatry Neurosci."},{"key":"2000_CR28","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/sj.mp.4002000","volume":"12","author":"R Kaddurah-Daouk","year":"2007","unstructured":"Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007;12:934\u201345.","journal-title":"Mol Psychiatry."},{"key":"2000_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psychres.2012.09.041","volume":"207","author":"WP Hoen","year":"2013","unstructured":"Hoen WP, Lijmer JG, Duran M, Wanders RJ, van Beveren NJ, de Haan L. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res. 2013;207:1\u201312.","journal-title":"Psychiatry Res."},{"key":"2000_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.neubiorev.2016.06.002","volume":"76","author":"M Schneider","year":"2017","unstructured":"Schneider M, Levant B, Reichel M, Gulbins E, Kornhuber J, Muller CP. Lipids in psychiatric disorders and preventive medicine. Neurosci Biobehav Rev. 2017;76:336\u201362.","journal-title":"Neurosci Biobehav Rev."},{"key":"2000_CR31","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.schres.2014.06.004","volume":"158","author":"R Emsley","year":"2014","unstructured":"Emsley R, Chiliza B, Asmal L, du Plessis S, Phahladira L, van Niekerk E, et al. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophr Res. 2014;158:230\u20135.","journal-title":"Schizophr Res."},{"key":"2000_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/mp.2011.131","volume":"18","author":"J Yang","year":"2013","unstructured":"Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, et al. Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013;18:67\u201378.","journal-title":"Mol Psychiatry."},{"key":"2000_CR33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.biopsych.2020.07.012","volume":"89","author":"AM Dickens","year":"2021","unstructured":"Dickens AM, Sen P, Kempton MJ, Barrantes-Vidal N, Iyegbe C, Nordentoft M, et al. Dysregulated lipid metabolism precedes onset of psychosis. Biol Psychiatry. 2021;89:288\u201397.","journal-title":"Biol Psychiatry."},{"key":"2000_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1006-3","volume":"16","author":"DK Solberg","year":"2016","unstructured":"Solberg DK, Bentsen H, Refsum H, Andreassen OA. Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study. Bmc Psychiatry. 2016;16:299.","journal-title":"Bmc Psychiatry."},{"key":"2000_CR35","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.schres.2018.03.029","volume":"199","author":"A Checa","year":"2018","unstructured":"Checa A, Malmqvist A, Flyckt L, Schwieler L, Samuelsson M, Skogh E, et al. Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients. Schizophr Res. 2018;199:438\u201341.","journal-title":"Schizophr Res."},{"key":"2000_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3109\/08039488.2011.605172","volume":"66","author":"M Coppola","year":"2012","unstructured":"Coppola M, Mondola R. Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: A review. Nord J Psychiat. 2012;66:73\u20138.","journal-title":"Nord J Psychiat."},{"key":"2000_CR37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/BF02256596","volume":"8","author":"NS Chu","year":"2001","unstructured":"Chu NS. Effects of betel chewing on the central and autonomic nervous systems. J Biomed Sci. 2001;8:229\u201336.","journal-title":"J Biomed Sci."},{"key":"2000_CR38","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.euroneuro.2010.10.007","volume":"21","author":"P Bubber","year":"2011","unstructured":"Bubber P, Hartounian V, Gibson GE, Blass JP. Abnormalities in the tricarboxylic acid (TCA) cycle in the brains of schizophrenia patients. Eur Neuropsychopharmacol. 2011;21:254\u201360.","journal-title":"Eur Neuropsychopharmacol."},{"key":"2000_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.226","volume":"6","author":"B Dean","year":"2016","unstructured":"Dean B, Thomas N, Scarr E, Udawela M. Evidence for impaired glucose metabolism in the striatum, obtained postmortem, from some subjects with schizophrenia. Transl Psychiatry. 2016;6:e949.","journal-title":"Transl Psychiatry."},{"key":"2000_CR40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fncel.2014.00195","volume":"8","author":"S Raboune","year":"2014","unstructured":"Raboune S, Stuart JM, Leishman E, Takacs SM, Rhodes B, Basnet A, et al. Novel endogenous N-acyl amides activate TRPV1-4 receptors, BV-2 microglia, and are regulated in brain in an acute model of inflammation. Front Cell Neurosci. 2014;8:195.","journal-title":"Front Cell Neurosci."},{"key":"2000_CR41","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S1734-1140(12)70879-4","volume":"64","author":"VS Rao","year":"2012","unstructured":"Rao VS, Carvalho AC, Trevisan MTS, Andrade GM, Nobre HV, Moraes MO, et al. Mangiferin ameliorates 6-hydroxydopamine-induced cytotoxicity and oxidative stress in ketamine model of schizophrenia. Pharm Rep. 2012;64:848\u201356.","journal-title":"Pharm Rep."},{"key":"2000_CR42","doi-asserted-by":"publisher","first-page":"e22127","DOI":"10.1002\/syn.22127","volume":"73","author":"B Garip","year":"2019","unstructured":"Garip B, Hakan Kayir. Alteration in NMDAR-related amino acids in first episode psychosis. Synapse. 2019;73:e22127.","journal-title":"Synapse."},{"key":"2000_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02517-z","volume":"20","author":"CM Teigset","year":"2020","unstructured":"Teigset CM, Mohn C, Rund BR. Perinatal complications and executive dysfunction in early-onset schizophrenia. BMC Psychiatry. 2020;20:103.","journal-title":"BMC Psychiatry."},{"key":"2000_CR44","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/mp.2016.6","volume":"21","author":"M Gupta","year":"2016","unstructured":"Gupta M, Neavin D, Liu D, Biernacka J, Hall-Flavin D, Bobo WV, et al. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. Mol Psychiatry. 2016;21:1717\u201325.","journal-title":"Mol Psychiatry."},{"key":"2000_CR45","doi-asserted-by":"publisher","first-page":"e005465","DOI":"10.1161\/JAHA.116.005465","volume":"6","author":"CL Lowery 3rd","year":"2017","unstructured":"Lowery CL 3rd, Elliott C, Cooper A, Hadden C, Sonon RN, Azadi P, et al. Cigarette Smoking-Associated alterations in serotonin\/adrenalin signaling pathways of platelets. J Am Heart Assoc. 2017;6:e005465.","journal-title":"J Am Heart Assoc."},{"key":"2000_CR46","first-page":"114","volume":"21","author":"DM Lovinger","year":"1997","unstructured":"Lovinger DM. Serotonin\u2019s role in alcohol\u2019s effects on the brain. Alcohol Health Res World. 1997;21:114\u2013120.","journal-title":"Alcohol Health Res World."}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02000-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02000-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02000-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T19:35:48Z","timestamp":1669232148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02000-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2000"],"URL":"https:\/\/doi.org\/10.1038\/s41398-022-02000-1","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DSC is a scientific advisory board member of Peptron Inc. Peptron had no role in the preparation, review, or approval of the manuscript. SC has served as a speaker for Otsuka Pharmaceuticals and has received grants from AstraZeneca as co-PI. CMS serves as a scientific advisor for Outermost Therapeutics Inc. SE discloses grant support from AstraZeneca and Jansen Pharmaceuticals as principal investigator and has been a speaker for Roche Pharmaceuticals, AstraZeneca, Eli Lilly, Orion Corporation Orion Pharma, and Bristol Myers Squibb (none of these are relevant to this work). All other authors declare no biomedical financial interests or potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}